Insulet Reports Full Year 2024 Revenue Increase of 22% and Fourth Quarter 2024 Revenue Increase of 17% Year-Over-Year
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Insulet Corporation (PODD) PT Raised to $310 at BTIG
February 21, 2025 5:09 AM ESTBTIG analyst Marie Thibault raised the price target on Insulet Corporation (NASDAQ: PODD) to $310.00 (from $300.00) while maintaining a Buy rating.
The analyst comments "Insulet reported Q4 revenue of $597.5M (+17% y/y), beating the consensus estimate of $583M and above the top end of the ~$571-$586M guidance range. U.S. Omnipod revenue of $443.7M (+12.4% y/y) was ~$7.5M above consensus of $436.3M while International Omnipod revenue of $142.0 (+33.1% cc y/ y) was ~$2M higher than consensus. Drug Delivery sales were $11.8M (cons. $6.5M). Type 2 patients were >30% of new U.S. starts in Q4... More
